View ValuationNeuren Pharmaceuticals 향후 성장Future 기준 점검 6/6Neuren Pharmaceuticals (는) 각각 연간 44.6% 및 32% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 49.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 38.5% 로 예상됩니다.핵심 정보44.6%이익 성장률49.38%EPS 성장률Pharmaceuticals 이익 성장14.5%매출 성장률32.0%향후 자기자본이익률38.50%애널리스트 커버리지Good마지막 업데이트19 May 2026최근 향후 성장 업데이트공시 • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.모든 업데이트 보기Recent updates공시 • Apr 25Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026. Location: racv city club, level 2, bayside 4a/b, 501 bourke st, melbourne vic 3000 Australia공시 • Apr 24Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025. Location: the event centre, level 5, tower 2, 727 collins st, melbourne vic 3000 Australia공시 • Feb 27Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Neuren Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Feb 28, 2025공시 • May 28Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins SyndromeNeuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as their parents and siblings. The open label Phase 2 trial in 16 children aged 3 to 17 years (mean age 9 years) at five hospitals in the United States examined safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591. NNZ-2591 was administered to all subjects as an oral liquid dose twice daily, with escalation in two stages up to the target dose of 12 mg/kg during the first 6 weeks of treatment, subject to independent review of safety and tolerability data. The study commenced with at least 4 weeks of screening and observation to thoroughly define baseline characteristics prior to treatment, followed by the treatment period of 13 weeks. A follow-up assessment was made 2 weeks after the end of treatment. The primary endpoints of this first trial in children with PTHS were safety, tolerability and pharmacokinetics. Secondary endpoints included four efficacy measures specifically designed for PTHS assessed by clinicians and by caregivers, as well as ten efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. NNZ-2591 was well tolerated and demonstrated a good safety profile. All Treatment Emergent Adverse Events (TEAEs) were mild to moderate and most were considered not related to study drug. There were no Serious TEAEs and no meaningful trends in laboratory values, electrocardiogram (ECG) or other safety parameters were observed during treatment. 11 subjects completed the trial. One subject discontinued because they were unable to complete the safety monitoring procedures required by the study protocol. Four subjects discontinued due to TEAEs, all of which resolved. For two of those subjects the TEAEs (COVID-19 and mild vomiting/diarrhea/lethargy) were considered not related to study drug and for two subjects the TEAEs (moderate constipation/self-injury/abdominal distention/fatigue and mild sleep disorder/constipation) were considered related to study drug. The mean improvement from baseline was statistically significant (Wilcoxon signed rank test p<0.05) for each of the four efficacy measures that were specifically designed for Pitt Hopkins syndrome, whether calculated for the subjects that completed the study (n=11), or including discontinued subjects (n=15). Changes from baseline were not statistically significant for the efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. The results for the global measures rated by both clinicians and caregivers showed a level of improvement considered clinically meaningful. 9 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Improvement (CGI-I), an assessment by the clinician of the child's overall status compared with baseline. The mean CGI-I score was 2.6. Five children received a score of either 1 ("very much improved") or 2 ("much improved"). 8 out of 11 children that completed the trial showed improvement measured by the PTHS Caregiver Overall Impression of Change (CIC), an assessment by the caregiver of the child's overall status compared with baseline. The mean CIC score was 3.0. Four children received a score of 2 ("much improved"). out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Severity (CGI-S), an assessment by the clinician of the child's overall severity of illness, compared with the assessment at baseline. The CGI-S score improved from 6 to 5 for 3 children and from 5 to 4 for 3 children. 8 out of 11 children that completed the trial showed improvement measured by the Caregiver Top 3 Concerns overall score, an individualised assessment by the caregiver of their child's most concerning symptoms. Language/Communication was the most commonly chosen concern.공시 • Apr 28Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024, at 14:30 E. Australia Standard Time. Location: FB Rice, Level 33 477 Collins St, Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the annual report of the Company; to Re-Election of Patrick Davies as a Director; to consider Auditor Fees and Expenses.공시 • Feb 29Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024Neuren Pharmaceuticals Limited announced that they will report Q4, 2023 results on Feb 29, 2024공시 • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.공시 • Aug 25Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023Neuren Pharmaceuticals Limited announced that they will report first half, 2023 results on Aug 28, 2023공시 • Jan 23Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDANeuren Pharmaceuticals Limited announced that the US Food and Drug Administration (FDA) has reviewed Neuren's Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome (PWS) and given approval for Neuren to proceed with the planned Phase 2 clinical trial in children with PWS. Neuren is developing NNZ-2591 for four serious neurological disorders that emerge in early childhood. Phase 2 trials are currently ongoing in children with each of Angelman, Phelan-McDermid and Pitt Hopkins syndromes, for which there are no approved medicines. All four programs have been granted Orphan Drug designation by the FDA. Neuren previously reported positive results in the Magel2-null mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits.공시 • Sep 23Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 TrialsNeuren Pharmaceuticals Limited has initiated the manufacture of NNZ-2591 to supply the planned Phase 2 clinical trials. The contract manufacturer that supplied drug substance for the ongoing Phase 1 trial will carry out this larger scale manufacturing campaign. Neuren plans to commence Phase 2 trials in patients with each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in 2021. Neuren has received Orphan Drug esignation from the FDA for NNZ-2591 to treat all three of these debilitating disorders that currently have no approved medicines.공시 • Aug 06Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,972 Price\Range: AUD 1.4공시 • Jul 08Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in fundingOn July 6, 2020, Neuren Pharmaceuticals Limited (ASX:NEU) closed the transaction. The company issued 14,285,723 shares for gross proceeds of AUD 20,000,012.2 in the transaction.공시 • Jun 30Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in fundingNeuren Pharmaceuticals Limited (ASX:NEU) announced a private placement of 14,285,714 common shares at AUD 1.40 per share for gross proceeds of AUD 20,000,000 on June 29, 2020. The transaction will include participation from institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the United Kingdom. The company expects to close the transaction on July 6, 2020.이익 및 매출 성장 예측OTCPK:NURP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028159177224168412/31/2027147583132412/31/202674141415412/31/20256530125125N/A9/30/202514290131131N/A6/30/2025219149138138N/A3/31/20252181466363N/A12/31/2024217142-11-11N/A9/30/20242061305454N/A6/30/2024195117119120N/A3/31/2024214137152152N/A12/31/2023232157185185N/A9/30/2023155106120120N/A6/30/202378555454N/A3/31/202347282929N/A12/31/202215044N/A9/30/20229-3-3-3N/A6/30/20223-7-10-10N/A3/31/20223-7-10-10N/A12/31/20213-8-10-10N/A9/30/20212-10-10-10N/A6/30/20211-12-9-9N/A3/31/20211-11-9-9N/A12/31/20201-9-8-8N/A9/30/20201-8-9-9N/A6/30/20200-8-9-9N/A3/31/20200-9-10-10N/A12/31/20190-11-12-12N/A9/30/20197-6N/A-5N/A6/30/201914-1N/A2N/A3/31/2019141N/A4N/A12/31/2018143N/A6N/A9/30/201873N/A0N/A6/30/201813N/A-6N/A3/31/201813N/A-6N/A12/31/201713N/A-6N/A9/30/20172-2N/A-7N/A6/30/20173-8N/A-8N/A3/31/20173-10N/A-10N/A12/31/20163-12N/A-12N/A9/30/20162-14N/A-14N/A6/30/20160-15N/A-17N/A3/31/20161-14N/A-15N/A12/31/20152-13N/A-13N/A9/30/20152-11N/A-11N/A6/30/20153-9N/A-8N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NURP.F 의 연간 예상 수익 증가율(44.6%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: NURP.F 의 연간 수익(44.6%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: NURP.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: NURP.F 의 수익(연간 32%)이 US 시장(연간 11.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NURP.F 의 수익(연간 32%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NURP.F의 자본 수익률은 3년 후 38.5%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 05:58종가2026/05/11 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neuren Pharmaceuticals Limited는 10명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterElyse ShapiroCanaccord Genuity7명의 분석가 더 보기
공시 • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.
공시 • Apr 25Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026. Location: racv city club, level 2, bayside 4a/b, 501 bourke st, melbourne vic 3000 Australia
공시 • Apr 24Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025. Location: the event centre, level 5, tower 2, 727 collins st, melbourne vic 3000 Australia
공시 • Feb 27Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Neuren Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
공시 • May 28Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins SyndromeNeuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as their parents and siblings. The open label Phase 2 trial in 16 children aged 3 to 17 years (mean age 9 years) at five hospitals in the United States examined safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591. NNZ-2591 was administered to all subjects as an oral liquid dose twice daily, with escalation in two stages up to the target dose of 12 mg/kg during the first 6 weeks of treatment, subject to independent review of safety and tolerability data. The study commenced with at least 4 weeks of screening and observation to thoroughly define baseline characteristics prior to treatment, followed by the treatment period of 13 weeks. A follow-up assessment was made 2 weeks after the end of treatment. The primary endpoints of this first trial in children with PTHS were safety, tolerability and pharmacokinetics. Secondary endpoints included four efficacy measures specifically designed for PTHS assessed by clinicians and by caregivers, as well as ten efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. NNZ-2591 was well tolerated and demonstrated a good safety profile. All Treatment Emergent Adverse Events (TEAEs) were mild to moderate and most were considered not related to study drug. There were no Serious TEAEs and no meaningful trends in laboratory values, electrocardiogram (ECG) or other safety parameters were observed during treatment. 11 subjects completed the trial. One subject discontinued because they were unable to complete the safety monitoring procedures required by the study protocol. Four subjects discontinued due to TEAEs, all of which resolved. For two of those subjects the TEAEs (COVID-19 and mild vomiting/diarrhea/lethargy) were considered not related to study drug and for two subjects the TEAEs (moderate constipation/self-injury/abdominal distention/fatigue and mild sleep disorder/constipation) were considered related to study drug. The mean improvement from baseline was statistically significant (Wilcoxon signed rank test p<0.05) for each of the four efficacy measures that were specifically designed for Pitt Hopkins syndrome, whether calculated for the subjects that completed the study (n=11), or including discontinued subjects (n=15). Changes from baseline were not statistically significant for the efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. The results for the global measures rated by both clinicians and caregivers showed a level of improvement considered clinically meaningful. 9 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Improvement (CGI-I), an assessment by the clinician of the child's overall status compared with baseline. The mean CGI-I score was 2.6. Five children received a score of either 1 ("very much improved") or 2 ("much improved"). 8 out of 11 children that completed the trial showed improvement measured by the PTHS Caregiver Overall Impression of Change (CIC), an assessment by the caregiver of the child's overall status compared with baseline. The mean CIC score was 3.0. Four children received a score of 2 ("much improved"). out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Severity (CGI-S), an assessment by the clinician of the child's overall severity of illness, compared with the assessment at baseline. The CGI-S score improved from 6 to 5 for 3 children and from 5 to 4 for 3 children. 8 out of 11 children that completed the trial showed improvement measured by the Caregiver Top 3 Concerns overall score, an individualised assessment by the caregiver of their child's most concerning symptoms. Language/Communication was the most commonly chosen concern.
공시 • Apr 28Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024, at 14:30 E. Australia Standard Time. Location: FB Rice, Level 33 477 Collins St, Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the annual report of the Company; to Re-Election of Patrick Davies as a Director; to consider Auditor Fees and Expenses.
공시 • Feb 29Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024Neuren Pharmaceuticals Limited announced that they will report Q4, 2023 results on Feb 29, 2024
공시 • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.
공시 • Aug 25Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023Neuren Pharmaceuticals Limited announced that they will report first half, 2023 results on Aug 28, 2023
공시 • Jan 23Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDANeuren Pharmaceuticals Limited announced that the US Food and Drug Administration (FDA) has reviewed Neuren's Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome (PWS) and given approval for Neuren to proceed with the planned Phase 2 clinical trial in children with PWS. Neuren is developing NNZ-2591 for four serious neurological disorders that emerge in early childhood. Phase 2 trials are currently ongoing in children with each of Angelman, Phelan-McDermid and Pitt Hopkins syndromes, for which there are no approved medicines. All four programs have been granted Orphan Drug designation by the FDA. Neuren previously reported positive results in the Magel2-null mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits.
공시 • Sep 23Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 TrialsNeuren Pharmaceuticals Limited has initiated the manufacture of NNZ-2591 to supply the planned Phase 2 clinical trials. The contract manufacturer that supplied drug substance for the ongoing Phase 1 trial will carry out this larger scale manufacturing campaign. Neuren plans to commence Phase 2 trials in patients with each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in 2021. Neuren has received Orphan Drug esignation from the FDA for NNZ-2591 to treat all three of these debilitating disorders that currently have no approved medicines.
공시 • Aug 06Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,972 Price\Range: AUD 1.4
공시 • Jul 08Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in fundingOn July 6, 2020, Neuren Pharmaceuticals Limited (ASX:NEU) closed the transaction. The company issued 14,285,723 shares for gross proceeds of AUD 20,000,012.2 in the transaction.
공시 • Jun 30Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in fundingNeuren Pharmaceuticals Limited (ASX:NEU) announced a private placement of 14,285,714 common shares at AUD 1.40 per share for gross proceeds of AUD 20,000,000 on June 29, 2020. The transaction will include participation from institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the United Kingdom. The company expects to close the transaction on July 6, 2020.